The
View from Here
Ulrike Knies-Bamforth, Editor Drug Discovery Today
With this issue, the first year of E-Choice is coming to an end. It
has been a successful launch and I would like to thank all the Guest
Editors for their valuable contributions. The focus of this month’s
E-Choice is our journal, Drug Discovery Today...
Read
more...
A
review of 2006
|
| |
Top
Reviews |
 |
I
want a new drug: G-protein-coupled receptors in drug development
Schlyer,
S. and Horuk, R.
Drug Discovery Today
Huey
Lewis and the News summed it up nicely in their 1980s hit record:
‘I want a new drug, one that won’t make me sick, one
that won’t make me crash my car, or make me feel three feet
thick’. The song could be an anthem for drug discovery in
the pharmaceutical industry...
|
| |
New
drug candidates and therapeutic targets for tuberculosis therapy
Zhang,
Y., Post-Martens, K., Denkin, S.
Drug Discovery Today
Despite
advances in chemotherapy and the BCG (Bacillus Calmette–Guérin)
vaccine, tuberculosis remains a significant infectious disease.
Although it can be cured, the therapy takes at least 6–9 months,
and the laborious and lengthy treatment brings with it dangers of
noncompliance, significant toxicity and drug resistance...
|
| |
Designing
better drugs: predicting cytochrome P450 metabolism
De
Groot, M.J.
Drug Discovery Today
Many
3D ligand-based and structure-based computational approaches have
been used to predict, and thus help explain, the metabolism catalyzed
by the enzymes of the cytochrome P450 superfamily (P450s). P450s
are responsible for >90% of the metabolism of all drugs, so the
computational prediction of metabolism can help to design out drug–drug
interactions...
|
| |
Harnessing
in vivo siRNA delivery for drug discovery and therapeutic
development
Xie
F.Y., Woodle, M.C., Lu, P.Y.
Drug Discovery Today
The
use of RNA interference (RNAi) is spreading rapidly to nearly every
aspect of biomedical research. The gene silencing capability of
RNAi is being used to study individual gene’s biological function
and role in biochemical pathways. However, the efficacy of RNAi
depends upon efficient delivery of the intermediates of RNAi, short
interfering RNA (siRNA) and short hairpin RNA (shRNA) oligonucleotides...
|
|
| |
Abstracts
of Key Research Articles
Novel
GPCR screening approach: indirect identification of S1P receptor
agonists in antagonist screening using a calcium assay
Siehler, S. and Guerini, D.
J Recept Signal Transduct Res. 26(5-6):549-75
GLIDA:
GPCR-ligand database for chemical genomic drug discovery
Okuno, Y., Yang, J., Taneishi, K., Yabuuchi, H., Tsujimoto, G.
Nucleic Acids Res. 34(Database issue):D673-7
GPCR
agonists and antagonists in the clinic
Tyndall, J.D. and Sandilya, R.
J Med Chem. 1(4):405-21
A
case for passive immunoprophylaxis against tuberculosis
Reljic, R. and Ivanyi, J.
Lancet Infect Dis. 6(12):813-8
Proteome-wide
profiling of isoniazid targets in Mycobacterium tuberculosis
Argyrou, A., Jin, L., Siconilfi-Baez, L., Angeletti, R.H., Blanchard,
J.S.
Biochemistry. 45(47):13947-53
Dissecting
virulence pathways of Mycobacterium tuberculosis through protein-protein
association
Singh, A., Mai, D., Kumar, A., Steyn, A.J.
Proc Natl Acad Sci USA 103(30):11346-51
Cytochrome
P450 nomenclature, 2004
Nelson, D.R.
Methods Mol Biol. 320:1-10
Crystal
structure of human cytochrome P450 2D6
Rowland, P., Blaney, F.E., Smyth, M.G., Jones, J.J., Leydon, V.R.,
Oxbrow, A.K., Lewis, C.J., Tennant, M.G., Modi, S., Eggleston,
D.S., Chenery, R.J., Bridges, A.M.
J Biol Chem. 17;281(11):7614-22
Ligand-targeted
delivery of therapeutic siRNA
Ikeda, Y., Taira, K.
Pharm Res. 23(8):1631-40
Cell
type-specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J.O. 2nd, Andrechek, E.R., Wang, Y., Viles, K.D., Rempel,
R.E., Gilboa, E., Sullenger, B.A., Giangrande, P.H.
Nat Biotechnol. 24(8):1005-15
Aptamer
mediated siRNA delivery
Chu, T.C., Twum K.Y., Ellington, A.D., Levy, M.
Nucleic Acids Res. 1;34(10):e73
|
|
